Rising prescription drug costs: Whose responsibility?

被引:8
作者
Hill, SR
Henry, DD
Smith, AJ
机构
关键词
D O I
10.5694/j.1326-5377.1997.tb138752.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:6 / 7
页数:2
相关论文
共 5 条
[1]  
*COMM DEP HUM SER, 1995, GUID PHARM IND PREP
[2]  
MARLEY J, 1996, AUST PRESCR, V19, P58
[3]   EFFECTS OF LIMITING MEDICAID DRUG-REIMBURSEMENT BENEFITS ON THE USE OF PSYCHOTROPIC AGENTS AND ACUTE MENTAL-HEALTH-SERVICES BY PATIENTS WITH SCHIZOPHRENIA [J].
SOUMERAI, SB ;
MCLAUGHLIN, TJ ;
ROSSDEGNAN, D ;
CASTERIS, CS ;
BOLLINI, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (10) :650-655
[4]   PAYMENT RESTRICTIONS FOR PRESCRIPTION DRUGS UNDER MEDICAID - EFFECTS ON THERAPY, COST, AND EQUITY [J].
SOUMERAI, SB ;
AVORN, J ;
ROSSDEGNAN, D ;
GORTMAKER, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (09) :550-556
[5]  
Soumerai SB, 1997, AUST PRESCR, V20, P28